Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs.

Nejatollahi F, Ranjbar R, Younesi V, Asgharpour M.

Oncol Res. 2013;20(8):333-40. doi: 10.3727/096504013X13657689382734.

PMID:
23924853
[PubMed - indexed for MEDLINE]
2.

Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies.

Nejatollahi F, Asgharpour M, Jaberipour M.

Med Oncol. 2012 Mar;29(1):378-83. doi: 10.1007/s12032-010-9796-5. Epub 2011 Jan 26.

PMID:
21267676
[PubMed - indexed for MEDLINE]
3.

Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells.

Nejatollahi F, Jaberipour M, Asgharpour M.

Tumour Biol. 2014 Aug;35(8):7887-95. doi: 10.1007/s13277-014-1854-8. Epub 2014 May 15.

PMID:
24828011
[PubMed - in process]
4.

Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.

Clin Cancer Res. 2009 Jun 15;15(12):4147-56. doi: 10.1158/1078-0432.CCR-08-2814. Epub 2009 Jun 9.

PMID:
19509167
[PubMed - indexed for MEDLINE]
Free Article
5.

FOXO1A is a target for HER2-overexpressing breast tumors.

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.

Cancer Res. 2010 Jul 1;70(13):5475-85. doi: 10.1158/0008-5472.CAN-10-0176. Epub 2010 Jun 15.

PMID:
20551062
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

64Cu-DOTA hu4D5v8 (scFv-CH2-CH3)2.

Cheng KT.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2006 Apr 11 [updated 2008 Apr 03].

PMID:
20641754
[PubMed]
Books & Documents
7.

124I-Labeled anti-HER2-specific C6.5 diabody.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 May 22 [updated 2011 Aug 04].

PMID:
21834183
[PubMed]
Books & Documents
8.
9.

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.

PMID:
23117856
[PubMed - indexed for MEDLINE]
10.
11.

Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.

Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, Jordan VC.

Eur J Cancer. 2012 Dec;48(18):3488-98. doi: 10.1016/j.ejca.2012.04.020. Epub 2012 Jun 2.

PMID:
22658320
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.

Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH, Dittmar T.

J Pathol. 2012 Jun;227(2):234-44. doi: 10.1002/path.3991. Epub 2012 Mar 21. Erratum in: J Pathol. 2013 May;230(1):e1.

PMID:
22262199
[PubMed - indexed for MEDLINE]
13.

Sensitization of breast cancer cells to radiation by trastuzumab.

Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z.

Mol Cancer Ther. 2003 Nov;2(11):1113-20.

PMID:
14617784
[PubMed - indexed for MEDLINE]
Free Article
14.

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.

Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J.

Cancer Res. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. Epub 2010 Oct 26.

PMID:
20978202
[PubMed - indexed for MEDLINE]
Free Article
16.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

PMID:
21492444
[PubMed - indexed for MEDLINE]
Free PMC Article
17.
18.

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.

Fischgräbe J, Götte M, Michels K, Kiesel L, Wülfing P.

Int J Cancer. 2010 Aug 1;127(3):696-706. doi: 10.1002/ijc.25076.

PMID:
19960438
[PubMed - indexed for MEDLINE]
19.

Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.

Yao YD, Sun TM, Huang SY, Dou S, Lin L, Chen JN, Ruan JB, Mao CQ, Yu FY, Zeng MS, Zang JY, Liu Q, Su FX, Zhang P, Lieberman J, Wang J, Song E.

Sci Transl Med. 2012 Apr 18;4(130):130ra48. doi: 10.1126/scitranslmed.3003601.

PMID:
22517885
[PubMed - indexed for MEDLINE]
Free Article
20.

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R.

Breast Cancer Res. 2011 Aug 31;13(4):R84. doi: 10.1186/bcr2936.

PMID:
21884573
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk